We’re at an interesting juncture: After years of offshoring, the pendulum is swinging back. Post-COVID disruptions and policy shifts, like the Trump-era tariffs have, accelerated the reshoring trend. bit.ly/3IsDxux

TSMC posted strong earnings, showing little impact from tariffs. Their $100B U.S. investment underscores the reshoring trend. With AI chip demand surging, domestic semiconductor production is set to drive both supply chain resilience and long-term investment potential. $TSM $RSHO

When measured correctly, domestic content in US manufacturing goods sold has been declining for decades. Most recently it has stabilized and started to inflect. For investors and policymakers alike, this stabilization could mark the beginning of a longer-term reshoring cycle.

This chart highlights a powerful dynamic: businesses with wide, defensible moats may generate significantly higher cash flow returns on investment than the broader market. In a world chasing short-term growth, long-term quality compounding remains a key investment opportunity.

AstraZeneca’s $50B U.S. investment by 2030 is a major tailwind for biotech & reshoring themes. It boosts domestic drug manufacturing, bolsters supply chain resilience, and supports innovation. #biotech #reshoring

At Tema, we focus on identifying companies with durable moats across 5 key dimensions. These are mission-critical businesses—essential to their customers, often delivering recurring revenues & strong returns. In a noisy market, quality endures. Learn more: bit.ly/3GMcEkF

Quality companies tend to do well during inflationary regimes. Why? Recurring revenues, often directly linked to inflation. As inflation persists, this could be a timely strategy to navigate today’s evolving market regime. Learn more here: bit.ly/4nS8Izn

Did you know that an AI-powered Google search can consume up to 10x more energy than a standard query? As AI advances, its growing computational demands are fueling a sharp rise in global energy consumption, further bolstering the $7T investment opportunity in electrification.

U.S. electricity demand is accelerating—and for the first time in decades, it's on track to outpace supply. This growing energy gap could catalyze a long-term investment cycle across the power value chain. #infrastructure #energytransition #electrification #investing

Real assets with inflation-linked revenues—like toll roads, airports, and railroads—offer powerful pricing moats. Even firms like Visa or Moody’s benefit as spending or debt issuance rises with inflation. In today’s market, that linkage matters more than ever.

After decades of decline, U.S. manufacturing is staging a comeback. Tariffs, industrial policy, and supply chain risks are driving a new era of reshoring—one that could reshape global production and create compelling investment opportunities.

🚨 Active ETFs brought in a record $44.8B in July—highlighting a secular shift in how investors and advisors are alike are seeking differentiated opportunities. Active ETFs are rapidly gaining market share and the data is there. morningstar.com/funds/active-e…

U.S. power demand is set to rise steadily, driven by renewables, EVs, and data centers. This shift underscores a $7T opportunity in electrification—requiring major investment in grid upgrades, storage, and distribution to meet the future of energy.

Apple just announced a $100B boost to U.S. manufacturing—on top of its $500B February pledge. Apple’s move signals growing momentum behind reshoring, tightening domestic supply chains, and the revival of U.S. manufacturing. $AAPL #reshoring #manufacturing

Oncology spending is projected to nearly double by 2027—driven by innovation, broader access, and an expanding pipeline of advanced therapies across cancer types. As the market scales, oncology remains one of the most compelling long-term themes in healthcare investing.

The rise of AI—and the relentless demand for computing power—is driving a surge in global data center capacity. As workloads scale, so does energy demand, making electrification and next-gen infrastructure one of the most compelling investment themes of the decade.

The anti-obesity drug market is projected to near $100B by 2030. These therapies go far beyond weight loss—unlocking real impact on cardiovascular outcomes. Innovation in cardiometabolic health is becoming a major pillar of long-term healthcare investing.